摘要
肺癌是全世界高死亡率癌症之一，在美國癌症死亡病例中，罹患肺癌者男性佔43％，女性佔25％，在台灣則女、男分居癌症死亡率的第一、二位，其全球發生率仍在上升中。儘管積極地給予治療，仍有6％肺癌病人開刀時無法完全切除，14％病人在治療一年後死亡，顯示肺癌診斷仍有改善空間。正子檢查可反應腫瘤的生化變化，FDG在肺部可呈現高標的／背景比例，因此FDG-PET已成為肺癌評估的重要工具，有經驗的核醫醫師可以藉腫瘤病理變化、淋巴引流或轉移機轉等配合定位影像進一步提供臨床醫師所需的資料。随著醫療科技的進步，FDG-PET除了應用在肺癌診斷與分期評估外，更應用在治療計畫與療效評估上。在美國PET及PET-CT已進入臨床應用階段，對社會醫療行為、病人醫療品質與存活的影響將在可預見的未來顯現。
並列摘要
Lung cancer is responsible for 32% of all cancer deaths in men and 25% in women in the United States It also ranked first in women(17.3%)and ranked second in men(23.2%)of cancer death here in Taiwan. The incidence of lung cancer is still increasing globally. In United States, despite the curative intention to treat the disease, about 6% of patients are unresectable at surgery and 14% die in one year. Improvement of the diagnostic strategy in lung cancer is thus needed. Positron emission tomography(PET)imaging can reflect the biochemical processes in cancers. Due to the high cancer-to-background ratio in lung parenchyma, 2-[18F]fluoro-2-deoxy-D-glucose(FDG)has become the most commonly used radiopharmaceutical in the clinical oncology. The clinical applications of FDG PET imaging has moved beyond the clinical diagnosis and initial staging for lung cancer. The current applications of PET and especially PET-CT focus on the treatment planning for lung cancer. Continued advances in computer, electronic and crystal technology and development of new biotracers have resulted in improved management of lung cancer by functional PET imaging in the diagnosis, staging, treatment planning and evaluation of therapeutic responses. PET and PET-CT has moved into the main stream of clinical applications, which may prove to impact greatly on the patient survival in the years to come.